Acadia Pharmaceuticals

Pharmaceutical company, which developed Nuplazid, based in San Diego, California.

ACAD Nasdaq ISIN US0042251084 SEC CIK 1070494
Follow Acadia Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $342.3M +22.8% vs same quarter last year
Net income $53.5M −25.4% vs same quarter last year
EPS, diluted $0.31 −26.2% vs same quarter last year
Operating cash flow $11.5M −84.5% vs same quarter last year
Revenue by quarter
$259.6M
$244.3M
$264.6M
$278.6M
$284M
$268.1M
$308M
$342.3M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$500M$0$500M$1B$1.5BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$1.1B$391M
FY24$957.8M$226M
FY23$726.4M−$61M
FY22$517.2M−$214M
FY21$484.1M−$168M
FY20$441.8M−$281.6M
FY19$339.1M−$235.3M
FY18$223.8M−$245.2M
FY17$124.9M−$289.4M
FY16$17.3M−$271.4M
FY15$61K−$164.4M
FY14$120K−$92.5M
FY13$1.1M−$37.9M
FY12$4.9M−$20.8M
FY11$2.1M−$22.8M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−300000%−200000%−100000%0%100000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2591.7%9.8%36.5%
FY2491.5%24.1%23.6%
FY2394.3%−10.1%−8.4%
FY2298%−43.2%−41.4%
FY2197.8%−35.2%−34.7%
FY2097.7%−64.9%−63.7%
FY1996.7%−72.7%−69.4%
FY1894.5%−110.6%−109.6%
FY1792.7%−234.1%−231.7%
FY1682.2%−1574.1%−1565.9%
FY15-−269855.7%−269578.7%
FY14-−77691.7%−77062.5%
FY13-−3344.7%−3314.2%
FY12-−425.6%−424.9%
FY11-−1105.6%−1101.4%
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0$100M$200MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$105.1M
FY24$157.2M
FY23$16.7M
FY22−$114M
FY21−$126.8M
FY20−$143.8M
FY19−$152.3M
FY18−$169.6M
FY17−$218.6M
FY16−$209.9M
FY15−$123.9M
FY14−$66.6M
FY13−$32.4M
FY12-
FY11−$19.9M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Acadia Pharmaceuticals
  • Healthcare median
−300000%−200000%−100000%0%100000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearAcadia PharmaceuticalsHealthcare median
FY2536.5%−30.6%
FY2423.6%−47%
FY23−8.4%−58%
FY22−41.4%−80.4%
FY21−34.7%−71.9%
FY20−63.7%−62.2%
FY19−69.4%−46.3%
FY18−109.6%−49.6%
FY17−231.7%−45.9%
FY16−1565.9%−36%
FY15−269578.7%−38.4%
FY14−77062.5%−35.5%
FY13−3314.2%−37.1%
FY12−424.9%−29.1%
FY11−1101.4%−27.9%